0000000000148594

AUTHOR

Giulia Morace

0000-0003-1696-1183

showing 4 related works from this author

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

How to manage aspergillosis in non-neutropenic intensive care unit patients.

2014

Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level …

medicine.medical_specialtyPediatricsChronic ObstructiveAntifungal AgentsCritical IllnessPopulationPulmonary diseaseSettore MED/41 - AnestesiologiaReviewNeutropeniaOpportunistic InfectionsAspergillosisCritical Care and Intensive Care MedicineCommunicable DiseasesCommunicable Diseases Emerginglaw.inventionPulmonary DiseaseImmunocompromised HostPulmonary Disease Chronic ObstructiveAspergillosis non-neutropenic ICUlawAdrenal Cortex HormonesRisk FactorsEpidemiologymedicinenon-neutropenicPrevalenceAspergillosisHumansIntensive care medicineeducationEmergingeducation.field_of_studybusiness.industryIncidence (epidemiology)Medicine (all)IncidenceAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicinemedicine.diseasePrognosisIntensive care unitAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised HostIntensive Care UnitsCohortICUAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicine; Medicine (all)businesssepsis aspergillosis icu managementCritical care (London, England)
researchProduct

A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents

2016

AbstractA phosphorylated peptide, named K40H, derived from the constant region of IgMs was detected in human serum by liquid chromatography coupled to high-resolution mass spectrometry. Synthetic K40H proved to exert a potent in vitro activity against fungal pathogens, and to inhibit HIV-1 replication in vitro and ex vivo. It also showed a therapeutic effect against an experimental infection by Candida albicans in the invertebrate model Galleria mellonella. K40H represents the proof of concept of the innate role that naturally occurring antibody fragments may exert against infectious agents, shedding a new light upon the posthumous role of antibodies and opening a new scenario on the multif…

0301 basic medicineMicrobial Sensitivity TestsVirus ReplicationArticleMass SpectrometryMicrobiology03 medical and health sciencesAnti-Infective AgentsCandida albicansHumansPhosphorylationCandida albicansInfectivityMultidisciplinaryInnate immune system030102 biochemistry & molecular biologybiologybiology.organism_classificationVirologyPeptide FragmentsIn vitroImmunoglobulin Fc FragmentsGalleria mellonella030104 developmental biologyImmunoglobulin MHumoral immunityHIV-1biology.proteinAntibodyEx vivoChromatography LiquidScientific Reports
researchProduct

Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy) pyrazole derivatives

2011

The antibacterial and antifungal activity of a series of products, in which the 1,5-dimethyl-4-(cyano- NNO-azoxy)pyrazol-3-yl and 1,3-dimethyl-4-(cyano-NNO-azoxy)pyrazol-5-yl moieties were linked to pyridine, pyrazole, isoxazole, thiophene and the furan ring, were examined. No molecule displayed activity against the Gram-negative bacteria tested. Conversely, some compounds displayed activity against two Staphylococcus aureus strains, including the methicillin resistant strain. All compounds displayed interesting antifungal activity, the most active compound of the series being the thiophene derivative 7a. This compound’s activity against Candida krusei and Candida glabrata (MIC = 0.25 and 0…

AzoxyStaphylococcus aureusAntifungal AgentsStereochemistryClinical BiochemistryPharmaceutical ScienceMicrobial Sensitivity TestsPyrazoleBiochemistryChemical synthesisAntifungal activity Pyrazole Azole sistance Cyano-NNO-azoxy Thiophenechemistry.chemical_compoundAnti-Infective AgentsThiopheneCandida kruseiNitrilesDrug DiscoveryThiopheneAntifungal activityIsoxazoleAntifungal activity; Pyrazole; Azole resistance; Cyano-NNO-azoxy; Thiophene.Molecular BiologyCandidaMolecular StructurebiologyCandida glabrataOrganic ChemistryBiological activitybiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticachemistryCyano-NNO-azoxyPyrazoleAzole resistancePyrazolesMolecular MedicineAzo Compounds
researchProduct